Cargando…

Humoral signatures of MOG-antibody-associated disease track with age and disease activity

Myelin oligodendrocyte glycoprotein (MOG)-antibody (Ab)-associated disease (MOGAD) is an inflammatory demyelinating disease of the CNS. Although MOG is encephalitogenic in different mammalian species, the mechanisms by which human MOG-specific Abs contribute to MOGAD are poorly understood. Here, we...

Descripción completa

Detalles Bibliográficos
Autores principales: Spatola, Marianna, Chuquisana, Omar, Jung, Wonyeong, Lopez, Joseph A., Wendel, Eva-Maria, Ramanathan, Sudarshini, Keller, Christian W., Hahn, Tim, Meinl, Edgar, Reindl, Markus, Dale, Russell C., Wiendl, Heinz, Lauffenburger, Douglas A., Rostásy, Kevin, Brilot, Fabienne, Alter, Galit, Lünemann, Jan D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9975090/
https://www.ncbi.nlm.nih.gov/pubmed/36669487
http://dx.doi.org/10.1016/j.xcrm.2022.100913
Descripción
Sumario:Myelin oligodendrocyte glycoprotein (MOG)-antibody (Ab)-associated disease (MOGAD) is an inflammatory demyelinating disease of the CNS. Although MOG is encephalitogenic in different mammalian species, the mechanisms by which human MOG-specific Abs contribute to MOGAD are poorly understood. Here, we use a systems-level approach combined with high-dimensional characterization of Ab-associated immune features to deeply profile humoral immune responses in 123 patients with MOGAD. We show that age is a major determinant for MOG-antibody-related immune signatures. Unsupervised clustering additionally identifies two dominant immunological endophenotypes of MOGAD. The pro-inflammatory endophenotype characterized by increased binding affinities for activating Fcγ receptors (FcγRs), capacity to activate innate immune cells, and decreased frequencies of galactosylated and sialylated immunoglobulin G (IgG) glycovariants is associated with clinically active disease. Our data support the concept that FcγR-mediated effector functions control the pathogenicity of MOG-specific IgG and suggest that FcγR-targeting therapies should be explored for their therapeutic potential in MOGAD.